与代谢综合征相关的氧化应激是一种复杂的疾病实体，已成为一项重大的公共卫生挑战，并且与心血管疾病、2 型糖尿病甚至癌症的风险升高密切相关。本研究的目的是探讨补充硒在控制氧化应激方面的有效性，同时考虑基于健康生活方式和饮食疗法的均衡饮食。该研究共有 206 名参与者，分为三组：对照组包括其中35人（17.0%）名为LC，饮食治疗组由119人（57.8%）组成，名为LD，饮食治疗组由52人（25.2%）组成，名为LD Se。评估了各种临床参数，如体重指数 (BMI)、体重状况、脂肪量、内脏脂肪和肌少症指数，以及临床旁参数，包括 HOMA 指数、胆固醇、甘油三酯、C 反应蛋白和 HGZ。此外，还使用 ​​FORD、FORT 和 MIXT 测试测量了氧化应激参数。补充硒以及 FORD 和 FORT 测试在患有慢性静脉疾病的个体中显示出有效性，并且在 LD 患有慢性静脉疾病的个体中观察到显着更大的降低硒族。生理衰老在引发或加重氧化应激方面具有重要作用，使用硒等抗氧化产品可以减少这一过程。版权所有 © 2023，国际抗癌研究所（Dr. George J. Delinasios），所有权利预订的。

Oxidative stress in association with metabolic syndrome represents a complex disease entity that has emerged as a significant public health challenge, and it is closely linked to an elevated risk of cardiovascular disease, type 2 diabetes, and even cancer. The objective of this study was to investigate the effectiveness of selenium supplementation in managing oxidative stress while considering a well-balanced diet based on a healthy lifestyle and diet therapy.The study included a total of 206 participants divided into three groups: the control group consisting of 35 individuals (17.0%) named LC, the diet therapy group comprising 119 individuals (57.8%) named LD, and the diet therapy group supplemented with selenium consisting of 52 individuals (25.2%) named LD+Se. Various clinical parameters such as body mass index (BMI), weight status, fat mass, visceral fat, and sarcopenia index, as well as paraclinical parameters including the HOMA index, cholesterol, triglycerides, C-reactive protein, and HGZ, were evaluated. Additionally, oxidative stress parameters using the FORD, FORT and MIXT tests were measured.Selenium supplementation, along with FORD and FORT tests, demonstrated effectiveness in individuals with chronic venous disease, with a significantly greater decrease observed in those with chronic venous disease in the LD+Se group.Physiological aging has an important role in triggering or aggravating oxidative stress, and the use of antioxidant products such as selenium can reduce this process.Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.